Organogenesis reported data from the P-III study assessing the safety and efficacy of ReNu (2mL diluted with 2mL of saline or 4mL saline control, one intra-articular injection) vs saline control for managing symptoms among moderate to severe symptomatic knee OA patients (n=515)
The study met its 1EPs, depicting knee pain reduction & maintained patient function after utilizing ReNu vs saline control at 6mos. with same AEs seen at 12mos. follow-up. Full analysis is anticipated in May. Another ReNu study is actively recruiting with full recruitment anticipated in 2024
ReNu is a cryopreserved ASA containing amniotic fluid cells, micronized amniotic membrane, growth factors & extracellular matrix components
Ref: Organogenesis Inc. | Image: Organogenesis
Related News:- Organogenesis Reverse Merges with Avista Healthcare Public Acquisition Corp. (AHPAC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
